HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

AbstractPURPOSE:
The phenotypic manifestations of cerebral cavernous malformation disease caused by rare PDCD10 mutations have not been systematically examined, and a mechanistic link to Rho kinase-mediated hyperpermeability, a potential therapeutic target, has not been established.
METHODS:
We analyzed PDCD10 small interfering RNA-treated endothelial cells for stress fibers, Rho kinase activity, and permeability. Rho kinase activity was assessed in cerebral cavernous malformation lesions. Brain permeability and cerebral cavernous malformation lesion burden were quantified, and clinical manifestations were assessed in prospectively enrolled subjects with PDCD10 mutations.
RESULTS:
We determined that PDCD10 protein suppresses endothelial stress fibers, Rho kinase activity, and permeability in vitro. Pdcd10 heterozygous mice have greater lesion burden than other Ccm genotypes. We demonstrated robust Rho kinase activity in murine and human cerebral cavernous malformation vasculature and increased brain vascular permeability in humans with PDCD10 mutation. Clinical phenotype is exceptionally aggressive compared with the more common KRIT1 and CCM2 familial and sporadic cerebral cavernous malformation, with greater lesion burden and more frequent hemorrhages earlier in life. We first report other phenotypic features, including scoliosis, cognitive disability, and skin lesions, unrelated to lesion burden or bleeding.
CONCLUSION:
These findings define a unique cerebral cavernous malformation disease with exceptional aggressiveness, and they inform preclinical therapeutic testing, clinical counseling, and the design of trials.Genet Med 17 3, 188-196.
AuthorsRobert Shenkar, Changbin Shi, Tania Rebeiz, Rebecca A Stockton, David A McDonald, Abdul Ghani Mikati, Lingjiao Zhang, Cecilia Austin, Amy L Akers, Carol J Gallione, Autumn Rorrer, Murat Gunel, Wang Min, Jorge Marcondes De Souza, Connie Lee, Douglas A Marchuk, Issam A Awad
JournalGenetics in medicine : official journal of the American College of Medical Genetics (Genet Med) Vol. 17 Issue 3 Pg. 188-196 (Mar 2015) ISSN: 1530-0366 [Electronic] United States
PMID25122144 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine
  • Apoptosis Regulatory Proteins
  • CCM2 protein, human
  • Carrier Proteins
  • Intracellular Signaling Peptides and Proteins
  • KRT1 protein, human
  • Keratin-1
  • Membrane Proteins
  • PDCD10 protein, human
  • PDCD10 protein, mouse
  • Proto-Oncogene Proteins
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases
Topics
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine (analogs & derivatives, pharmacology)
  • Adolescent
  • Adult
  • Animals
  • Apoptosis Regulatory Proteins (genetics, metabolism)
  • Carrier Proteins (genetics)
  • Cells, Cultured
  • Central Nervous System Neoplasms (enzymology, genetics, pathology)
  • Child
  • Child, Preschool
  • Disease Models, Animal
  • Hemangioma, Cavernous, Central Nervous System (enzymology, genetics, pathology)
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Infant
  • Intracellular Signaling Peptides and Proteins (genetics, metabolism)
  • Keratin-1 (genetics)
  • Membrane Proteins (genetics, metabolism)
  • Mice
  • Middle Aged
  • Mutation
  • Prospective Studies
  • Proto-Oncogene Proteins (genetics, metabolism)
  • Stress Fibers (drug effects, metabolism)
  • Young Adult
  • rho-Associated Kinases (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: